Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients

Pharmacogenetics and Genomics

Volumn 24, Issue 5, 2014, Pages 256-262

  Woillard, Jean Baptiste ^a,b   Picard, Nicolas ^a,b   Thierry, Antoine ^c   Touchard, Guy ^c   Marquet, Pierre ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 2C8; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ANEMIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; ENZYME METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY GRAFT; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ANALOGS AND DERIVATIVES; GENETICS; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; CARRIER PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 84898544550     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000045     Document Type: Article

References (27)

1. Budde K, Bauer S, Hambach P, Hahn U, Roblitz H, Mai I, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7:888-898.
2. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995; 49:1323-1329.
3. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33:139-146.
4. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004; 32:775-778.
5. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006; 34:1539-1545.
6. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002; 24:390-399.
7. Gensburger O, Picard N, Marquet P. Effect of mycophenolate acylglucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem 2009; 55:986-993.
8. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34:429-455.
9. Patel CG, Ogasawara K, Akhlaghi F. Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. Xenobiotica 2013; 43:229-235.
10. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 2006; 34:261-266.
11. Picard N, Yee SW,Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010; 87:100-108.
12. Picard N, Marquet P. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol 2011; 7:731-743.
13. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010; 11:369-390.
14. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82:1074-1084.
15. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation 2011; 91:309-316.
16. Bouamar R, Elens L, Shuker N, van Schaik RH, Weimar W, Hesselink DA, et al. Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. Transplantation 2012; 93:e39-e40, author reply e41-e42.
17. Thierry A, Mourad G, Buchler M, Kamar N, Villemain F, Heng AE, et al. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. Nephrol Dial Transplant 2012; 27:3651-3659.
18. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83: 1525-1535.
19. Stern ST, Tallman MN, Miles KK, Ritter JK, Dupuis RE, Smith PC. Genderrelated differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats. Drug Metab Dispos 2007; 35:449-454.
20. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008; 86:67-74.
21. Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30:673-683.
22. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26:600-608.
23. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-1325.
24. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17:321-330.
25. Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy 2010; 30:1097-1108.
26. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107-113.
27. Cattaneo D, Cortinovis M, Baldelli S, Bitto A, Gotti E, Remuzzi G, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007; 2:1147-1155.